Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × ralimetinib × Clear all
NCT01663857 2019-09-11

A Study LY2228820 for Recurrent Ovarian Cancer

Eli Lilly and Company

Phase 1/2 Completed
118 enrolled 18 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02364206 2019-08-14

GLYRad

Centre Jean Perrin

Phase 1/2 Completed
18 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡